Search Results for: covid-19
Articles
September 5, 2024
DRUG DELIVERY - Viewing Lipid Nanoparticle Delivery Technology Through the Lens of a CRDMO September 5, 2024
Lu Tian, PhD, says the complexity of LNP formulations demands diverse and integrated capabilities for development – incorporating lipids, oligonucleotides, small molecules, and sometimes antibodies or ligands, and thus it requires a cohesive approach.
September 5, 2024
SILICON-STABILIZED HYBRID LNPS - Next-Generation Delivery of RNA Therapeutics September 5, 2024
Suzanne Saffie-Siebert, PhD, Michael Welsh, PhD, Nissim Torabi-Pour, PhD, and Flavia M. Sutera, PhD, review current shortcomings, as well as some accompanying manufacturing challenges, and will show how they can be addressed by SiSaf’s silicon-stabilized hybrid LNPs.
August 20, 2024
Pharma CMO M&A Activity Shifts Focus to Scaling in 2023 August 20, 2024
Merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry declined in 2023 compared to 2021-22. High inflation and...
August 13, 2024
Evonik Expands its Formulation Capabilities for Lipid Nanoparticles Used for mRNA & Gene Therapies August 13, 2024
Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the upscaling of lipid nanoparticle...
July 31, 2024
GeoVax Announces Phase 2 Plans for Cancer Therapy Following Clinical Advisory Committee Review July 31, 2024
GeoVax Labs, Inc. recently announced the next steps for the clinical development of its Gedeptin cancer therapy, following a clinical...
July 30, 2024
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients With Newly Diagnosed, Advanced Ovarian Cancer Treated With IMNN-001 July 30, 2024
IMUNON, Inc. recently announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced...
July 11, 2024
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational July 11, 2024
Rentschler Biopharma SE recently announced the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC),...
July 3, 2024
CureVac Initiates Strategic Restructuring to Align Resources With Focus on High-Value mRNA Pipeline Opportunities July 3, 2024
CureVac N.V. recently announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other...
June 20, 2024
API & the University of Alberta Break Ground on Canada’s Largest Manufacturing Facility for Critical Medicines June 20, 2024
Construction is set to begin on a crucial pharmaceutical manufacturing facility in the Edmonton Research Park that will provide Canadians...
June 18, 2024
Truveta Announces Support for Regulatory Submissions to the FDA & Global Regulatory Authorities June 18, 2024
Truveta recently announced regulatory and audit capabilities to support its customers for real-world evidence (RWE) submissions to the US FDA...
June 6, 2024
Atriva Therapeutics Secures US Patent for First-in-Class Broad Spectrum Therapy for Severe RNA Virus Infections Including Bird Flu June 6, 2024
Atriva Therapeutics recently announced it has been granted a US patent for its MEK inhibitor zapnometinib (ATR-002). The patent includes...
June 5, 2024
First Participants Vaccinated in IMUNON’s Phase 1 Clinical Trial June 5, 2024
IMUNON, Inc. recently announced the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study...
June 4, 2024
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-Proof Antibody Against the SARS-CoV-2 Variant JN.1 June 4, 2024
ExeVir Bio recently announced new data demonstrating its antibodies are exceptionally potent in neutralizing the SARS-CoV-2 variant JN.1, the parental...
June 3, 2024
CONTAINER PLATFORMS - Ready-to-Use Containers: Real Benefits, Important Challenges & Evolving Value June 3, 2024
Gregor Deutschle and Gabriele Maier examine key benefits, dynamics driving the adoption of RTU container platforms, and several important areas of continuing evolution in the RTU market.
May 29, 2024
BioNTech & CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem May 29, 2024
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) are expanding their strategic partnership to contribute to building a sustainable...
May 13, 2024
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study May 13, 2024
IMUNON, Inc. recently announced DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for...
April 29, 2024
EXECUTIVE INTERVIEW - Cocrystal Pharma: Utilizing Structure-Based Technologies to Provide First- & Best-In-Class Antiviral Drugs to Address Critically Unmet Medical Needs April 29, 2024
Dr. Sam Lee, Cocrystal Pharma’s President and co-CEO, discusses the company’s latest achievements in antiviral drug development.
April 26, 2024
Oligonucleotides & mRNA Vaccines Dominate in Strategic Alliances for RNA Therapies in Major APAC Countries April 26, 2024
RNA-based therapies have already proven and will continue to play an integral role in the development of novel therapeutic agents...
April 26, 2024
CanSinoBIO CSO Shares Latest Results of Innovative Pneumococcal Vaccine April 26, 2024
On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the...
April 15, 2024
Naobios & Sumagen Sign Exclusive Partnership to Develop HIV Vaccine April 15, 2024
Naobios will manage process development and initiate launch of cGMP manufacturing for Phase 2 clinical trials….
